TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03304808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise Programme +device+ lubricant
Description: A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Programme + lubricant
Description: A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating
Study: NCT01985321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol/glycolic acid solution
Description: ethanol/glycolic acid solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Ethanol
Description: ethanol solution
Study: NCT01121016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10mg, qn, 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo to montelukast
Description: same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
Study: NCT02379858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
Study: NCT03758937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: volume-controlled ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure-controlled ventilation
Study: NCT03293680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) 200 mg, every 3 weeks
Study: NCT01883505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa
Description: Subcutaneous continuous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous continuous administration
Study: NCT01988415

Intervention type: DEVICE
Group type: OTHER
Intervention: VSS-Rx1 OPM vs Commercial iDesign Treatment
Description: Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
Study: NCT01750346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical acetyl hexapeptide-8
Study: NCT04045067

Intervention type: PROCEDURE
Intervention: Isolation of pulmonary veins
Description: Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.

Intervention type: PROCEDURE
Intervention: Isolation of pulmonary veins
Description: Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.

Intervention type: PROCEDURE
Intervention: Isolation of pulmonary veins
Description: Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.

Intervention type: PROCEDURE
Intervention: Ablation by radiofrequency of low-voltage areas
Description: The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
Study: NCT01802281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterosacral ligament suspension
Description: The USLS procedure used in this protocol is a modification of the technique described by Shull.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uphold® LITE
Description: The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
Study: NCT05303740

Intervention type: DRUG
Intervention: Anlotinib
Description: This is an observational study.
Study: NCT02295202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP (REMstar System One Plus - Philips Medical Systems)
Description: Standard device for treating obstructive sleep apnea.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal strips
Study: NCT01778244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1000mg/day for 24 weeks
Study: NCT03133767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: 2 liters of intravenous lactated ringers solution will be administered by peripheral IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: 2 liters of intravenous normal saline solution will be administered by peripheral IV
Study: NCT01175369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based Care
Description: The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
Study: NCT02570373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
Study: NCT01413893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linifanib
Description: QD daily
Study: NCT04493047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) for pneumonia
Description: Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
Study: NCT03664726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Episodic Recent Thinking
Description: Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Recent Thinking
Description: Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scarcity Narrative
Description: Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scarcity Narrative
Description: Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Narrative
Description: Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
Study: NCT01750346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical acetyl hexapeptide-8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03664726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Narrative
Description: Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
Study: NCT01543321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine
Description: Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators
Study: NCT00812487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Description: Patients will receive continuous insulin infusion through the vein.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin
Description: 4 injections of insulin/day
Study: NCT03291301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
Study: NCT01543217

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RT management
Description: Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ususal care
Description: Routine respiratory care.
Study: NCT01629381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 10 mg os once daily for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10 mg os once daily for 1 week
Study: NCT00852462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAMI
Description: Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
Study: NCT01125059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: 0.2 mg/kg methadone IV bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 mL saline IV bolus
Study: NCT01461421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Strategies
Description: Participants are taught self-monitoring and goal setting techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss Strategies
Description: Participants are taught self-monitoring and goal setting techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cognitive Techniques
Description: Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance Based Techniques
Description: Participants are taught how to accept and change their perception of their thoughts and emotions.
Study: NCT04606628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggshell membrane (ESM)
Description: The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks
Study: NCT02881255

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator
Description: Patients will be randomized to receive either a subcutaneous or transvenous ICD.

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator
Description: Patients will be randomized to receive either a subcutaneous or transvenous ICD.
Study: NCT03677492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Cytochalasin D
Description: A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
Study: NCT03949426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPG-818
Description: KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
Study: NCT04018482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone Iodine
Description: FDA-approved disinfectant for intravitreal injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypochlorous Acid
Description: FDA-approved disinfectant for intravitreal injections
Study: NCT00925119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: 12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
Study: NCT02778451

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of competence
Description: This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of competence
Description: This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
Study: NCT00900718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann Bone Ceramic
Description: Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
Study: NCT03957447

Intervention type: OTHER
Intervention: thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia
Description: Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
Study: NCT03291301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
Study: NCT03916107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Levator muscle and tarsus resection
Description: Shortening the levator muscle with resection of tarsus to correct severe ptosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frontalis flap
Description: Using frontal muscle flap to correct severe ptosis
Study: NCT03742648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
Study: NCT01983930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini yoga and meditation
Description: Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
Study: NCT03742648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
Study: NCT01633437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX157
Description: CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice per day on study days 4-11 and in the morning of day 12.
Study: NCT01995045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Retrobulbar anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine Hydrochloride
Description: Retrobulbar anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine Hydrochloride
Description: Retrobulbar anesthesia
Study: NCT04089215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Description: JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells
Study: NCT01136200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious disease specialist advice
Description: Indication, choice, dosing and duration of antimicrobial therapy
Study: NCT03473418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole as a topical vaginal gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole
Description: Terconazole 80 mg as a topical vaginal cream
Study: NCT02383225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lakota Language enhancement
Description: This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lakota Language enhancement
Description: This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Supplement
Description: This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Supplement
Description: This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use Resistance Skills
Description: This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use Resistance Skills
Description: This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
Study: NCT04235010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genius toothbrush
Description: Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual toothbrush
Description: Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
Study: NCT01543321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators
Study: NCT00814931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXB722
Description: 900 mg CXB722 oral liquid suspension twice a day for 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching oral liquid suspension placebo twice a day for 8 days